Companies › Hangzhou Huasai Biomedicine
1 active drug program in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HS-IT101 Injection Autologous tumor-infiltrating lymphocyte (TIL) therapy | – | Phase 2 | Melanoma (Excluding Uveal Melanoma); Advanced Non-Small Cell Lung Cancer; Solid Tumor; Clear Cell Renal Cell Carcinoma … | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07105176 | HS-IT101 Injection | Phase 1 | Advanced Non-Small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT07406724 | HS-IT101 Injection | Phase 2 | Melanoma (Excluding Uveal Melanoma) | Oncology | Dec 2027 |
| NCT06342336 | HS-IT101 Injection | Phase 1 | Solid Tumor | Oncology | Mar 2028 |
| NCT07770802 | HS-IT101 Injection | Phase 1 | Clear Cell Renal Cell Carcinoma | Oncology | Aug 2028 |
| NCT07830342 | HS-IT101 Injection | Phase 1 | Advanced NSCLC | Oncology | Oct 2028 |
No annotated target.
–
Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.